Please login to the form below
Dr Malte Peters joins MorphoSys
He succeeds Dr Arndt Schottelius as chief development officer
Germany-based therapeutic antibodies specialist MorphoSys has appointed Dr Malte Peters as its new chief development officer, succeeding Dr Arndt Schottelius from 1 March.
Dr Peters joins MorphoSys from Sandoz, where he served as global head of clinical development in its biopharmaceuticals business unit.
Prior to this, he was Novartis' clinical head of oncology translational medicine and head of its Basel and East Hanover sites, and served as head of translational research and pharmacogenomics at Merck KGaA.
During this time he also held teaching appointments in internal medicines and biochemistry at the University of Mainz, in Germany.
Dr Gerald Möller, chairman of MorphoSys' supervisory board, said: “Dr Peters is an ideal addition to the management board of MorphoSys at this stage of the company's growth.
“Drawing on his deep operational and medical experience in oncology and immunology, he will focus his efforts on the development of our clinical and pre-clinical programmes, the most valuable assets driving out future growth.”
Subscribe to our email news alerts
- Planting the Seeds for Future Women Leaders in Medicine
- FDA approves SpringWork’s Ogsiveo as first therapy for desmoid tumours
- GSK shares positive phase 3 results for Blenrep combination in multiple myeloma
- Stem cell therapy trial shows promising results for treating progressive MS
- Cancer Research UK calls on government to create ten-year cancer plan
- Risk calculator to prevent heart attacks and strokes in type 2 diabetes patients
No results were found
PMHub
Graphite Digital
We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
